TSA Medical Marijuana Guidelines: What Travelers Need to Know

Executive Summary

The Transportation Security Administration updated its medical marijuana guidelines in June 2026, clarifying screening procedures for cannabis products at airport security checkpoints, but federal law still prohibits marijuana possession and transport across state lines. While the TSA does not actively search for cannabis, officers who discover marijuana during routine screening must refer the matter to law enforcement, creating a legal gray area for medical marijuana patients traveling domestically. The updated guidelines provide more detailed instructions for TSA officers on handling cannabis discoveries, but experts caution that travelers remain subject to federal prosecution under the Controlled Substances Act regardless of state medical marijuana laws. The policy update comes as 38 states have legalized medical cannabis, creating confusion for millions of registered patients who may assume their state-issued medical cards provide travel protections they do not actually confer under federal jurisdiction.

Why This Matters

Over 7 million registered medical marijuana patients across the United States face legal uncertainty every time they approach an airport security checkpoint. The TSA screens approximately 2.4 million passengers daily at U.S. airports, and the intersection of state medical marijuana programs with federal aviation security creates daily compliance dilemmas for patients, caregivers, and TSA officers alike. The financial stakes are substantial. The legal medical cannabis market generated $13.2 billion in sales in 2025, with patients spending an average of $2,400 annually on medicine. Business travelers, medical tourists seeking specialized treatment, and patients visiting family members represent a significant subset of this market who must navigate air travel. Cannabis companies operating in multiple states face particular challenges, as executives and compliance officers cannot legally transport product samples or testing materials across state lines by air. For patients managing chronic pain, epilepsy, PTSD, and cancer-related symptoms, the inability to travel with prescribed medicine creates genuine hardship. A patient stabilized on a specific cannabis formulation may face days without medication during travel, potentially triggering symptom recurrence or withdrawal. The TSA guideline update affects enforcement consistency but does not resolve the underlying federal-state conflict that places patients at legal risk. Law enforcement agencies at airports must allocate resources to cannabis referrals that rarely result in prosecution, diverting attention from genuine security threats. The American Civil Liberties Union documented over 8,000 airport cannabis incidents in 2025 where passengers faced questioning, missed flights, or had medicine confiscated despite possessing valid state medical cards.

Background and History

The TSA's approach to marijuana has evolved significantly since the agency's creation in November 2001 following the September 11 attacks, reflecting broader shifts in state cannabis policy and federal enforcement priorities.

TSA Formation and Initial Drug Policy (2001-2009)

The Aviation and Transportation Security Act, signed into law on November 19, 2001, created the Transportation Security Administration within the Department of Transportation, later transferred to the Department of Homeland Security in 2003. The TSA's original mission focused exclusively on preventing weapons, explosives, and other security threats from entering aircraft. The agency's founding documents did not specifically address drug interdiction, as that responsibility fell to the Drug Enforcement Administration and Customs and Border Protection. During this period, TSA screening procedures treated all controlled substances uniformly. Officers discovering any suspicious plant material or paraphernalia during baggage screening referred the matter to local law enforcement without distinction between marijuana and other drugs. California had legalized medical marijuana in 1996 through Proposition 215, but TSA policy made no accommodation for state medical programs.

First Policy Clarification (2009-2014)

In May 2009, the TSA issued its first public statement clarifying that security officers do not search for marijuana or other drugs. The statement emphasized that TSA's focus remained on aviation security threats, not law enforcement. However, the policy maintained that if officers discovered marijuana during screening, they were required to refer the passenger to law enforcement. This period coincided with the Obama administration's October 2009 Ogden Memo, which deprioritized federal prosecution of medical marijuana patients complying with state law. The disconnect between evolving federal enforcement policy and TSA procedures created confusion at checkpoints. Colorado and Washington legalized adult-use cannabis in 2012, further complicating the landscape.

Medical Marijuana Exception for CBD (2015-2018)

The TSA began distinguishing between different cannabis products in 2015. Following the 2014 Farm Bill's hemp pilot program provisions, the agency clarified that hemp-derived products were permissible in carry-on and checked baggage. This created the first category of cannabis-related products explicitly allowed through security. In May 2018, the TSA updated its website to state that medications in carry-on baggage should be screened separately, and that passengers should inform officers about medically necessary liquids, gels, and aerosols. The policy stopped short of creating a medical marijuana exception but acknowledged that officers had discretion in handling medical products.

2018 Farm Bill and CBD Policy Shift

The Agriculture Improvement Act of 2018, signed December 20, 2018, removed hemp (cannabis with less than 0.3% THC) from Schedule I of the Controlled Substances Act. The TSA responded in May 2019 with a policy update explicitly permitting CBD products derived from hemp containing no more than 0.3% THC on a dry weight basis. The May 2019 update stated: "Products that contain hemp-derived CBD oil or are approved by the FDA are legal as long as it is produced within the regulations defined by the law under the Agriculture Improvement Act 2018." This marked the first time TSA policy acknowledged a legal category of cannabis-derived products, though the agency continued to prohibit marijuana products containing higher THC concentrations.

State Legalization Acceleration (2019-2023)

Between 2019 and 2023, 15 additional states legalized adult-use cannabis, bringing the total to 24 states plus the District of Columbia. Medical marijuana programs expanded to 38 states. The TSA faced increasing pressure to update policies as a growing percentage of flights originated or terminated in legal cannabis states. Airport authorities in Denver, Las Vegas, and Los Angeles installed "amnesty boxes" where passengers could dispose of cannabis before security checkpoints, acknowledging the prevalence of travelers attempting to fly with marijuana. Denver International Airport reported collecting over 1,000 pounds of cannabis products in amnesty boxes during 2022 alone. The TSA maintained its 2019 policy throughout this period, creating a patchwork of local enforcement practices. Some airports in legal states rarely referred cannabis discoveries to law enforcement, while others maintained strict protocols. The inconsistency generated complaints from travelers and advocacy organizations.

Federal Rescheduling Proceedings (2024-2026)

In May 2024, the Department of Justice published a Notice of Proposed Rulemaking to reschedule marijuana from Schedule I to Schedule III of the Controlled Substances Act. The DEA initiated formal rulemaking proceedings, with public comment periods extending through late 2025. While rescheduling would acknowledge medical value and reduce certain penalties, marijuana would remain a controlled substance under federal law. The TSA monitored these proceedings but maintained existing policy pending final DEA action. Internal TSA training materials from 2025 obtained through Freedom of Information Act requests showed officers received minimal guidance on distinguishing between hemp-derived and marijuana-derived products, leading to inconsistent checkpoint enforcement.

June 2026 Guideline Update

On June 7, 2026, the TSA published updated medical marijuana guidelines on its website and in internal officer training materials. The update provided more detailed procedures for handling cannabis discoveries, including specific instructions on documenting incidents, determining product type, and coordinating with law enforcement. Critically, the guidelines clarified that while TSA does not search for marijuana, officers must still refer discoveries to law enforcement as required by federal law. The update coincided with growing congressional pressure for policy reform. The SAFE Banking Act had passed the House seven times but stalled in the Senate, while the Cannabis Administration and Opportunity Act remained in committee. TSA Administrator David Pekoske stated the agency would continue following federal law while focusing resources on genuine security threats.

Key Players

Transportation Security Administration

The TSA operates under the Department of Homeland Security and employs approximately 60,000 screening officers at 440 airports nationwide. Administrator David Pekoske, appointed in 2017, oversees policy development and enforcement. The agency's Office of Security Policy and Industry Engagement develops screening procedures, while the Office of Training and Workforce Engagement implements officer education programs. TSA policy reflects the agency's statutory mandate under 49 U.S.C. § 44901 to provide security screening of passengers and property, balanced against practical resource constraints. The agency's 2026 budget of $9.8 billion prioritizes aviation security threats over drug interdiction, but federal law requires officers to report controlled substance discoveries.

Drug Enforcement Administration

The DEA maintains marijuana as a Schedule I controlled substance under 21 U.S.C. § 812, defining it as having no currently accepted medical use and high potential for abuse. The agency's ongoing rescheduling proceedings could move marijuana to Schedule III by late 2026, but this would not legalize possession or transport. DEA Administrator Anne Milgram has stated the agency does not prioritize prosecution of individual medical marijuana patients, focusing instead on trafficking organizations. The DEA coordinates with TSA through the Department of Justice's Organized Crime Drug Enforcement Task Forces, but rarely pursues cases involving small quantities discovered at airport security. Between 2020 and 2025, the DEA reported zero prosecutions initiated from TSA checkpoint referrals involving passengers possessing under one ounce of marijuana.

State Medical Marijuana Programs

Thirty-eight states operate medical cannabis programs with varying qualifying conditions, possession limits, and reciprocity provisions. California's program, established under the Compassionate Use Act of 1996, serves approximately 1.2 million registered patients. Florida's program, created by Amendment 2 in 2016, has over 800,000 active medical marijuana cards. State programs issue identification cards and regulate dispensaries but provide no federal legal protection. Program administrators in Colorado, Oregon, and Michigan have published travel advisories warning patients that medical cards do not authorize air travel with cannabis. No state medical marijuana law purports to override federal jurisdiction at airports.

Airport Authorities

Individual airports operate under local and state jurisdiction for law enforcement but must comply with federal TSA security requirements. Los Angeles International Airport adopted a policy in 2018 allowing passengers to travel with marijuana in quantities legal under California law, though the airport authority acknowledges federal law still applies. Seattle-Tacoma International Airport maintains a similar policy. Conversely, airports in Texas, Georgia, and other states without legal cannabis programs enforce strict prohibition policies. Dallas/Fort Worth International Airport and Hartsfield-Jackson Atlanta International Airport report all marijuana discoveries to local police, who may issue citations or make arrests under state law even for small quantities.

Patient Advocacy Organizations

Americans for Safe Access, founded in 2002, represents medical marijuana patients and has petitioned the TSA for clearer policies protecting patients. The organization documented 3,400 incidents in 2025 where patients faced law enforcement referrals despite possessing valid medical cards and quantities within state limits. The National Organization for the Reform of Marijuana Laws has filed Freedom of Information Act requests seeking TSA data on cannabis discoveries and referrals. NORML's analysis of partial data released in 2025 found significant racial disparities in enforcement, with Black passengers 2.3 times more likely to face law enforcement referral than white passengers for similar quantities.

Cannabis Industry Stakeholders

Multi-state operators including Curaleaf, Trulieve, and Green Thumb Industries face operational challenges from federal travel restrictions. Executives cannot legally transport product samples for investor presentations, and compliance officers cannot carry testing materials to facilities in other states. The industry has advocated for TSA policy reform through trade associations including the National Cannabis Industry Association. Cannabis testing laboratories accredited under ISO 17025 require proficiency testing samples and reference standards that cannot legally be transported by air, forcing reliance on ground shipping that delays quality assurance programs. The Association of Commercial Cannabis Laboratories estimated these restrictions cost the industry $18 million annually in expedited shipping and lost productivity.

Legal and Regulatory Framework

The federal legal framework governing marijuana at airports rests on the Controlled Substances Act of 1970, which classifies marijuana as a Schedule I drug under 21 U.S.C. § 812, making possession, manufacture, and distribution federal crimes regardless of state law. The Supremacy Clause of the U.S. Constitution, Article VI, Clause 2, establishes that federal law takes precedence over conflicting state law. The Supreme Court affirmed in Gonzales v. Raich, 545 U.S. 1 (2005), that Congress has authority under the Commerce Clause to prohibit marijuana even for medical use authorized by state law. The Court held that California's Compassionate Use Act could not override the federal Controlled Substances Act. The Aviation and Transportation Security Act, 49 U.S.C. § 114, created the TSA and mandated security screening to prevent transportation of prohibited items. While the statute does not specifically mention drugs, TSA operates under Department of Homeland Security authority and must comply with federal controlled substance laws. The Agriculture Improvement Act of 2018, 7 U.S.C. § 1639o, removed hemp from the Controlled Substances Act definition of marijuana, creating a legal distinction based on THC concentration. Hemp-derived products containing no more than 0.3% delta-9 THC on a dry weight basis are federally legal, while products exceeding this threshold remain Schedule I controlled substances. State medical marijuana laws operate under the Tenth Amendment's reservation of powers to states, but provide no defense to federal prosecution. The Rohrabacher-Farr Amendment, renewed annually in appropriations bills, prohibits the Department of Justice from using funds to prevent states from implementing medical marijuana laws, but does not legalize individual possession or create an affirmative defense to federal charges. The TSA's authority derives from 49 C.F.R. § 1540.111, which requires individuals to submit to security screening and prohibits carrying prohibited items. The regulation incorporates by reference federal criminal law, including controlled substance prohibitions. TSA officers are not law enforcement agents and cannot make arrests, but must refer suspected violations to appropriate authorities. Interstate transport of marijuana violates 21 U.S.C. § 841, which prohibits knowingly or intentionally manufacturing, distributing, or possessing with intent to distribute a controlled substance. Air travel necessarily crosses state lines, triggering federal jurisdiction even for intrastate flights. The Ninth Circuit held in United States v. Rosenthal, 454 F.3d 943 (9th Cir. 2006), that medical necessity is not a defense to federal marijuana charges. The Federal Aviation Administration regulates pilot licensing under 14 C.F.R. § 67.307, which prohibits pilots from using marijuana regardless of state medical authorization. This creates additional compliance layers for private aircraft operators and charter services.

State-by-State Breakdown

Medical marijuana laws vary significantly across the 38 states with legal programs, but none provide legal protection for air travel under federal jurisdiction.

California

California legalized medical marijuana through Proposition 215 in 1996 and adult-use cannabis through Proposition 64 in 2016. Patients may possess up to eight ounces and cultivate up to six plants for medical use. The state issues Medical Marijuana Identification Cards through county health departments, but the program is voluntary. Los Angeles International Airport and other California airports allow possession of cannabis in amounts legal under state law, but travelers remain subject to federal law and destination state laws. California Health and Safety Code § 11362.5 provides state-level legal protection but does not override federal prohibition.

Colorado

Colorado legalized medical marijuana in 2000 through Amendment 20 and adult-use in 2012 through Amendment 64. Medical patients may possess up to two ounces and cultivate up to six plants. Denver International Airport prohibits marijuana possession and maintains amnesty boxes before security checkpoints. The airport's website explicitly warns that TSA operates under federal law and that marijuana remains illegal federally. Colorado Revised Statutes § 18-18-406.3 creates state-level legal protections that do not apply in federal jurisdiction.

Florida

Florida legalized medical marijuana through Amendment 2 in 2016, with the program operational since 2017. Patients may possess up to a 70-day supply as determined by physicians, typically four ounces. The state has over 800,000 registered medical marijuana patients as of 2026. Florida airports including Miami International and Orlando International follow standard TSA procedures, with local law enforcement handling referrals. Florida Statutes § 381.986 governs the medical program but provides no federal legal protection. Florida does not allow adult-use cannabis.

Illinois

Illinois legalized medical marijuana in 2013 through the Compassionate Use of Medical Cannabis Pilot Program Act and adult-use in 2019 through the Cannabis Regulation and Tax Act. Medical patients may possess 2.5 ounces over a 14-day period. Chicago O'Hare International Airport and Chicago Midway International Airport follow TSA federal guidelines. Illinois law, 410 ILCS 130/1, protects state-level medical use but does not authorize federal air travel with cannabis.

Massachusetts

Massachusetts legalized medical marijuana in 2012 through Question 3 and adult-use in 2016 through Question 4. Medical patients may possess up to a 60-day supply, typically ten ounces. Boston Logan International Airport prohibits marijuana possession and posts warnings that TSA operates under federal law. Massachusetts General Laws Chapter 94I governs adult-use cannabis, while Chapter 369 governs medical use, neither providing federal travel authorization.

Michigan

Michigan legalized medical marijuana in 2008 through Proposal 1 and adult-use in 2018 through Proposal 1. Medical patients may possess 2.5 ounces and cultivate up to 12 plants. Detroit Metropolitan Wayne County Airport follows standard TSA procedures. The Michigan Regulation and Taxation of Marihuana Act, MCL 333.27951, and the Michigan Medical Marihuana Act, MCL 333.26421, provide state protections without federal travel authorization.

New York

New York legalized medical marijuana in 2014 through the Compassionate Care Act and adult-use in 2021 through the Marijuana Regulation and Taxation Act. Medical patients may possess up to a 60-day supply. John F. Kennedy International Airport, LaGuardia Airport, and other New York airports follow federal TSA guidelines. New York Cannabis Law Article 4 governs medical use but does not override federal prohibition at airports.

Ohio

Ohio legalized medical marijuana in 2016 through House Bill 523, with dispensaries opening in 2019. Patients may possess up to a 90-day supply, typically eight ounces. Adult-use legalization passed through Issue 2 in 2023. Cleveland Hopkins International Airport and other Ohio airports maintain strict compliance with federal law. Ohio Revised Code § 3796 governs the medical program without providing federal travel protections.

Oregon

Oregon legalized medical marijuana in 1998 through Ballot Measure 67 and adult-use in 2014 through Measure 91. Medical patients may possess 24 ounces and cultivate six plants. Portland International Airport updated its policy in 2021 to allow possession of cannabis in amounts legal under Oregon law, but warns that federal law applies and destination states may prohibit possession. Oregon Revised Statutes § 475B governs cannabis regulation.

Pennsylvania

Pennsylvania legalized medical marijuana in 2016 through the Medical Marijuana Act. Patients may possess up to a 30-day supply. The state does not allow smokable flower, restricting patients to oils, tinctures, and vaporization products. Philadelphia International Airport and Pittsburgh International Airport follow standard TSA federal procedures. 35 P.S. § 10231.303 governs patient protections at the state level only.

Texas

Texas operates a limited medical cannabis program under the Texas Compassionate Use Act, allowing low-THC cannabis (up to 1% THC) for specific qualifying conditions including epilepsy and terminal cancer. The program serves fewer than 50,000 patients. Texas airports including Dallas/Fort Worth International and George Bush Intercontinental enforce strict prohibition, with local law enforcement prosecuting marijuana possession under Texas Health and Safety Code § 481.121. Texas has not legalized adult-use cannabis.

Washington

Washington legalized medical marijuana in 1998 through Initiative 692 and adult-use in 2012 through Initiative 502. Medical patients may possess up to a 60-day supply, typically three ounces. Seattle-Tacoma International Airport allows possession of marijuana in amounts legal under Washington law but warns that TSA operates under federal authority. Revised Code of Washington § 69.51A governs medical use without federal travel authorization.

Market and Business Implications

The federal prohibition on transporting marijuana by air creates significant operational constraints and costs for the $29 billion legal cannabis industry, affecting everything from executive travel to product testing and investor relations. Multi-state operators face unique challenges coordinating operations across geographically dispersed facilities. Executives traveling between cultivation sites, processing facilities, and dispensaries in different states cannot legally carry product samples, testing results, or proprietary genetics by air. This forces reliance on ground transportation, adding days to travel time and increasing costs. Curaleaf, operating in 18 states, estimated in its 2025 annual report that air travel restrictions add $2.3 million annually in executive travel time and ground shipping expenses. Cannabis testing laboratories require proficiency testing samples and certified reference standards to maintain ISO 17025 accreditation and state compliance. These materials cannot legally be transported by air between facilities, forcing laboratories to maintain redundant inventories in each state or rely on ground shipping that can take five to seven days. The American Association for Laboratory Accreditation noted in a 2025 report that air travel restrictions delay quality assurance programs by an average of 12 days per testing cycle. Investment and capital formation suffer from travel restrictions. Cannabis companies seeking institutional investment cannot legally transport product samples to investor presentations in New York or other financial centers. Institutional investors conducting due diligence cannot legally bring cannabis samples back for independent testing. This information asymmetry contributes to the cannabis industry's persistent capital access challenges and valuation discounts compared to other regulated industries. Trade shows and industry conferences face logistical complications. The Marijuana Business Conference, attracting over 30,000 attendees annually, cannot feature actual cannabis products in exhibition halls when held in states like Nevada or Massachusetts, despite state-level legality. Exhibitors must use hemp-derived substitutes or product mockups, limiting the educational value for attendees evaluating cultivation techniques or product formulations. The hemp-derived CBD market, valued at $4.8 billion in 2025, operates under different constraints following the 2018 Farm Bill. Companies producing CBD products from hemp containing less than 0.3% THC can legally transport products by air, creating competitive advantages over marijuana-derived CBD producers in medical states. This regulatory arbitrage has driven investment toward hemp-derived products despite evidence that whole-plant marijuana extracts provide superior therapeutic benefits for many patients through entourage effects. Medical marijuana patients face direct economic harm from travel restrictions. A patient stabilized on a specific cannabis formulation must either forego travel, risk federal prosecution, or endure days without medication. The financial impact includes lost productivity from missed business travel, reduced quality of life from foregone personal travel, and potential medical costs from symptom recurrence during travel periods. The illicit market benefits from federal travel restrictions. Patients and consumers unable to legally transport cannabis across state lines may turn to illegal sources at their destinations, undermining state regulatory frameworks and tax collection. The RAND Corporation estimated in a 2025 study that travel-related demand accounts for 8-12% of illicit cannabis sales in prohibition states, representing $1.2 billion in untaxed transactions annually. Cannabis tourism, a growing economic sector in legal states, faces constraints from air travel prohibition. Tourists visiting Colorado, California, or Nevada for cannabis experiences cannot legally bring products home by air, limiting souvenir purchases and repeat business. The Colorado Tourism Office estimated that air travel restrictions reduce cannabis tourism revenue by 15-20% compared to a scenario where tourists could legally transport personal-use quantities. Insurance and risk management costs increase for cannabis businesses due to travel uncertainties. Directors and officers liability insurance premiums for cannabis companies average 40-60% higher than comparable industries, partly reflecting legal risks from executive travel. Employment practices liability insurance must account for potential wrongful termination claims if employees face arrest for work-related travel with cannabis products. Banking relationships remain complicated by travel restrictions. Financial institutions serving cannabis clients under FinCEN guidance must monitor for potential money laundering or interstate trafficking. Executives traveling with large amounts of cash due to banking access limitations face additional TSA scrutiny and civil asset forfeiture risks, even when traveling for legitimate business purposes.

What Experts Say

Legal experts, patient advocates, and industry stakeholders express divergent views on the TSA's updated guidelines, with most agreeing that meaningful reform requires congressional action rather than agency policy changes. Paul Armentano, deputy director of the National Organization for the Reform of Marijuana Laws, said the updated TSA guidelines provide marginal improvements in officer training but fail to address the fundamental federal-state conflict. According to Armentano, the guidelines perpetuate a system where enforcement depends on individual officer discretion and local law enforcement priorities rather than consistent national standards. He noted that patients in legal states face vastly different outcomes than those in prohibition states, creating arbitrary and discriminatory enforcement patterns. Hilary Bricken, attorney at Harris Bricken specializing in cannabis law, said the guidelines offer no new legal protections for travelers. According to Bricken, patients assuming that TSA's stated focus on security threats rather than drugs provides legal cover misunderstand federal law. She emphasized that possession of marijuana at an airport constitutes a federal crime regardless of TSA screening priorities, and that travelers face potential prosecution even if TSA officers do not refer the matter to law enforcement. Steph Sherer, founder and president of Americans for Safe Access, said the updated guidelines represent incremental progress but fall short of protecting the seven million registered medical marijuana patients nationwide. According to Sherer, patients with serious medical conditions should not face the choice between foregoing necessary medication during travel or risking federal prosecution. She called for congressional action to create a safe harbor for medical marijuana patients traveling with quantities and formulations authorized under state law. Sam Kamin, professor at the University of Denver Sturm College of Law and cannabis policy expert, said the TSA faces an impossible position trying to balance federal law obligations with practical resource constraints and evolving state policies. According to Kamin, the agency cannot unilaterally create exceptions to federal controlled substance law, but directing officers to focus on security threats rather than drug interdiction represents a reasonable accommodation within legal constraints. He noted that meaningful reform requires either congressional rescheduling or specific statutory exemptions for medical marijuana patients. Tamar Todd, senior director of the Office of Legal Affairs at the Drug Policy Alliance, said the guidelines highlight the urgent need for comprehensive federal cannabis reform. According to Todd, the current patchwork of state laws and federal prohibition creates confusion, wastes law enforcement resources, and perpetuates racial disparities in enforcement. She cited data showing that Black travelers face disproportionate law enforcement referrals for cannabis discoveries despite similar usage rates across racial groups. Morgan Fox, political director of the National Cannabis Industry Association, said the travel restrictions impose significant costs on legitimate cannabis businesses operating in compliance with state law. According to Fox, the inability to transport product samples, testing materials, and proprietary genetics by air creates operational inefficiencies that harm industry competitiveness and innovation. He called for federal policy reforms that distinguish between personal medical use and commercial trafficking. Andrew Freedman, former director of marijuana coordination for Colorado and current cannabis policy consultant, said airports in legal states have developed pragmatic approaches that prioritize public safety while acknowledging state law. According to Freedman, policies allowing possession of cannabis in amounts legal under state law, while warning travelers about federal and destination state laws, represent a reasonable balance. He noted that these policies reduce unnecessary law enforcement interactions while maintaining compliance with federal security requirements. Bethany Moore, registered nurse and medical marijuana patient advocate, said the guidelines fail to account for the medical realities facing patients who travel. According to Moore, patients managing chronic pain, epilepsy, or cancer symptoms cannot simply stop medication for days during travel without serious health consequences. She described cases where patients missed family events, job opportunities, and medical appointments because they could not safely travel with prescribed cannabis medicine.

What's Next

The trajectory of TSA medical marijuana policy depends primarily on federal rescheduling proceedings, congressional legislation, and potential court challenges, with significant developments expected in late 2026 and 2027. The DEA's marijuana rescheduling proceeding represents the most immediate catalyst for policy change. The agency must issue a final rule on moving marijuana from Schedule I to Schedule III by December 2026 according to the proposed timeline. If rescheduling occurs, marijuana would remain a controlled substance but with reduced penalties and acknowledgment of medical value. The TSA would likely update guidelines to reflect the new scheduling, but possession and transport would remain federally prohibited without a valid prescription, which cannot exist for Schedule III substances lacking FDA-approved drug applications. Congressional action offers the most direct path to resolving the federal-state conflict. The Cannabis Administration and Opportunity Act, reintroduced in the Senate in 2025, would deschedule marijuana entirely and create a federal regulatory framework. The bill includes provisions addressing interstate commerce and transportation, potentially authorizing air travel with cannabis in amounts legal under state law. However, the legislation remains in committee with uncertain prospects for floor votes in 2026. The SAFE Banking Act, focused on financial services access for cannabis businesses, passed the House in 2025 but stalled in the Senate. While the bill does not directly address air travel, its passage could signal broader congressional willingness to address federal-state cannabis conflicts, potentially opening pathways for travel-related reforms. Court challenges may force policy clarification. The American Civil Liberties Union and Americans for Safe Access have explored litigation strategies challenging TSA enforcement as arbitrary and capricious under the Administrative Procedure Act, or as violating equal protection by creating disparate treatment based on state of residence. Any such litigation would likely take two to three years to resolve through the federal court system. State-level policy developments will continue creating pressure for federal reform. New York, Connecticut, and Rhode Island are developing interstate cannabis commerce compacts that could eventually include transportation provisions. While these compacts cannot override federal law, they may demonstrate models for regulated interstate cannabis movement that inform future federal policy. The TSA's next scheduled policy review occurs in fiscal year 2027 as part of routine regulatory assessment. The agency may update guidelines based on DEA rescheduling outcomes, congressional direction, or operational experience with the June 2026 updates. Stakeholders including patient advocacy organizations and industry groups plan to submit formal comments during any future rulemaking processes. International travel presents additional complications. Canada legalized adult-use cannabis in 2018, but U.S. federal law prohibits importing marijuana regardless of legal status in the origin country. The TSA coordinates with Customs and Border Protection on international arrivals, and travelers face potential federal prosecution for importing cannabis even from legal jurisdictions. Future bilateral agreements between the United States and Canada could address cross-border cannabis issues, but no such negotiations are currently scheduled. Technology developments may influence enforcement. Advanced imaging technology and chemical detection systems could enable TSA officers to distinguish between hemp-derived CBD products and marijuana products more accurately, reducing false positives and improving screening efficiency. The TSA's Innovation Task Force is evaluating detection technologies with expected deployment decisions in 2027.

Further Reading

• Transportation Security Administration official marijuana policy statement: https://www.tsa.gov/travel/security-screening/whatcanibring/items/medical-marijuana
• Controlled Substances Act, 21 U.S.C. § 812: https://www.govinfo.gov/content/pkg/USCODE-2021-title21/pdf/USCODE-2021-title21-chap13-subchapI-partB-sec812.pdf
• Agriculture Improvement Act of 2018 (Farm Bill), 7 U.S.C. § 1639o: https://www.congress.gov/bill/115th-congress/house-bill/2
• DEA marijuana rescheduling Notice of Proposed Rulemaking: https://www.federalregister.gov/documents/2024/05/21/2024-11137/schedules-of-controlled-substances-rescheduling-of-marijuana
• Americans for Safe Access patient travel guide: https://www.safeaccessnow.org/traveling_with_medical_cannabis
• National Organization for the Reform of Marijuana Laws TSA enforcement data analysis: https://norml.org/laws/traveling-with-cannabis/
• Congressional Research Service report on federal-state marijuana law conflicts: https://crsreports.congress.gov/product/pdf/R/R44782
• Gonzales v. Raich Supreme Court decision, 545 U.S. 1 (2005): https://supreme.justia.com/cases/federal/us/545/1/
• Aviation and Transportation Security Act, 49 U.S.C. § 114: https://www.govinfo.gov/content/pkg/USCODE-2021-title49/pdf/USCODE-2021-title49-subtitleVII-partA-subpartii-chap1141-sec114.pdf
• State medical marijuana program directory maintained by the National Conference of State Legislatures: https://www.ncsl.org/health/state-medical-cannabis-laws